Daniel Afshin Akhavan, MD
Pulmonary Disease · Whittier
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 29 years
- Graduated 1997
Offices
1 location · Whittier Pulmonary and Critical Care Medical Group, Inc. · 15 clinicians in this group
Looking this up.
Hospitals listed: Pih Health Hospital-Whittier. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Akhavan’s office at (562) 789-5470 to ask if they take your plan before you enroll.
California Medical Board record
Licence A72347 · Current
Licensed to practise in California · since 2000 · expires 2028-05-31 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Pih Health Hospital-WhittierWhittier, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of PIH Health, which runs 3 hospitalsPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.497, Oct 2024 – Sep 2025
See every measure and the patient survey for Pih Health Hospital-Whittier
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.497 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.83 (0 to 1.8) · 1,222 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.77 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 165.59 (122.43 to 208.75) · 99 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 64 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 149 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 323 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.9 · 360 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 553 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 4,869 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.36) · 6,090 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.1 to 0.49) · 6,261 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.56 (3.44 to 7.67) · 1,178 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.98 (0.31 to 3.64) · 255 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.28 (1.77 to 4.79) · 1,113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.32 (5.89 to 20.76) · 256 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.43 to 9.49) · 249 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.16 to 3.11) · 236 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.12 (0 to 0.71) · 5,179 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 140 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.594 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.825 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.474 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.445 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.39 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 509 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 1,125 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.1 · 147 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27 · 401 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 30.4 · 400 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.3 · 1,019 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.3 to 7.4) · 71 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (10.4 to 18.1) · 71 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.6 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.4 · 222 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (10.1 to 16.6) · 1,770 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 397 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,178 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$78,213
Medicare paid this office $78,213 for 194 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 141 | $56,454 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $5,323 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,899 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,710 | $143 |
| Critical care, each additional 30 minutes | 28 | $2,696 | $87 |
See all 6 services
| Critical care, first 30-74 minutes | 141 | $56,454 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $5,323 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,899 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,710 | $143 |
| Critical care, each additional 30 minutes | 28 | $2,696 | $87 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,465 | $107 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Emergent insertion of breathing tube into windpipe using an endoscope | – | – | – | – | 12 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
194 Original Medicare patients in 2024. Average age 72 · Under 65 18% · 85 and older 14% · Women 53% · Also on Medicaid 60% · Health risk score 3.90. Sicker patients than 9 in 10 peers; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Heart failure 61% · Chronic kidney disease 60% · Diabetes 54% · Coronary heart disease 47% · Atrial fibrillation 39% · COPD 37% · Depression 36% · Stroke 35% · Dementia 23% · Cancer 19%.
The office billed $334,148, Medicare allowed $98,447 and paid $78,213; for 579 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 194 | 579 | 72 | 3.90 | $334,148 | $78,213 |
| 2023 | 228 | 738 | 73 | 3.18 | $441,524 | $106,375 |
| 2022 | 263 | 833 | 75 | 3.10 | $341,629 | $98,974 |
| 2021 | 196 | 586 | 74 | 2.94 | $204,407 | $66,696 |
| 2020 | 184 | 512 | 73 | 3.40 | $153,188 | $47,638 |
| 2019 | 264 | 693 | 74 | 3.16 | $213,274 | $68,984 |
| 2018 | 297 | 791 | 75 | 3.42 | $197,613 | $59,577 |
| 2017 | 328 | 887 | 74 | 3.03 | $218,785 | $67,880 |
| 2016 | 324 | 897 | 73 | 3.19 | $244,240 | $71,672 |
| 2015 | 315 | 900 | 74 | 3.14 | $247,758 | $74,704 |
| 2014 | 325 | 1,072 | 73 | 3.09 | $236,360 | $82,070 |
| 2013 | 303 | 937 | 75 | 3.15 | $170,861 | $73,128 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Critical care, first 30-74 minutes | 160 | $77,425 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 82 | $13,358 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $4,176 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $3,778 | $145 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,068 | $109 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 12 | $1,378 | $115 |
| Critical care, each additional 30 minutes | 11 | $1,065 | $89 |
2022: 12 services
| Critical care, first 30-74 minutes | 134 | $69,146 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $7,614 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $3,854 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,184 | $168 |
| Return visit (30+ min) | 17 | $2,585 | $108 |
| Critical care, each additional 30 minutes | 22 | $2,486 | $92 |
| Short return visit (20+ min) | 28 | $1,853 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,595 | $114 |
| New patient visit (30+ min) | 11 | $1,010 | $92 |
| Test to determine lung volumes using sensors | 38 | $328 | $9 |
| Test to examine how well the lungs exchange gases | 43 | $274 | $6 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $263 | $8 |
2021: 7 services
| Critical care, first 30-74 minutes | 107 | $46,346 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 57 | $7,499 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,595 | $88 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,118 | $86 |
| Test to determine lung volumes using sensors | 32 | $334 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 31 | $277 | $9 |
| Test to examine how well the lungs exchange gases | 33 | $255 | $8 |
2020: 9 services
| Critical care, first 30-74 minutes | 63 | $24,527 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 60 | $7,152 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $5,154 | $90 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 25 | $2,195 | $88 |
| Return visit (30+ min) | 20 | $1,470 | $74 |
| Critical care, each additional 30 minutes | 11 | $1,143 | $95 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $398 | $11 |
| Test to determine lung volumes using sensors | 33 | $354 | $11 |
| Test to examine how well the lungs exchange gases | 34 | $271 | $8 |
2019: 11 services
| Critical care, first 30-74 minutes | 104 | $43,195 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $7,281 | $62 |
| Return visit (30+ min) | 42 | $5,953 | $90 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 29 | $2,479 | $85 |
| Critical care, each additional 30 minutes | 22 | $2,438 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,499 | $88 |
| Short return visit (20+ min) | 11 | $650 | $54 |
| Test to determine lung volumes using sensors | 49 | $506 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 38 | $414 | $11 |
| Test to examine how well the lungs exchange gases | 53 | $407 | $8 |
| Test to measure expiratory airflow and volume | 16 | $116 | $7 |
2018: 10 services
| Critical care, first 30-74 minutes | 60 | $18,701 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 109 | $14,175 | $58 |
| Return visit (30+ min) | 53 | $7,444 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $6,510 | $83 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 33 | $2,612 | $79 |
| Long return visit (40+ min) | 15 | $1,784 | $111 |
| Critical care, each additional 30 minutes | 12 | $1,061 | $88 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 47 | $462 | $10 |
| Test to determine lung volumes using gas dilution or washout | 46 | $427 | $9 |
| Test to examine how well the lungs exchange gases | 49 | $338 | $7 |
2017: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 152 | $19,894 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 102 | $16,591 | $89 |
| Critical care, first 30-74 minutes | 42 | $12,057 | $188 |
| Return visit (30+ min) | 56 | $6,263 | $75 |
| Long return visit (40+ min) | 22 | $2,980 | $119 |
| Critical care, each additional 30 minutes | 19 | $2,645 | $94 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,403 | $78 |
| Test to determine lung volumes using gas dilution or washout | 33 | $337 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 31 | $334 | $11 |
| Test to examine how well the lungs exchange gases | 33 | $249 | $8 |
2016: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 161 | $21,233 | $59 |
| Critical care, first 30-74 minutes | 62 | $17,547 | $185 |
| Return visit (30+ min) | 64 | $8,818 | $85 |
| Long return visit (40+ min) | 43 | $7,094 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $4,783 | $84 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 35 | $2,856 | $82 |
| New patient visit (60+ min) | 11 | $1,845 | $168 |
| Critical care, each additional 30 minutes | 11 | $1,110 | $93 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $251 | $10 |
| Test to determine lung volumes using gas dilution or washout | 26 | $237 | $9 |
| Test to examine how well the lungs exchange gases | 26 | $175 | $7 |
2015: 12 services
| Critical care, first 30-74 minutes | 66 | $20,542 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 129 | $15,665 | $59 |
| Return visit (30+ min) | 76 | $11,860 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $7,521 | $85 |
| Long return visit (40+ min) | 27 | $4,592 | $121 |
| New patient visit (60+ min) | 13 | $2,118 | $163 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 23 | $1,913 | $83 |
| New patient visit (45+ min) | 13 | $1,783 | $137 |
| Critical care, each additional 30 minutes | 14 | $1,369 | $91 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $387 | $11 |
| Test to determine lung volumes using gas dilution or washout | 35 | $375 | $10 |
| Test to examine how well the lungs exchange gases | 35 | $279 | $8 |
2014: 13 services
| Critical care, first 30-74 minutes | 67 | $21,386 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 149 | $19,837 | $59 |
| Return visit (30+ min) | 84 | $13,618 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $5,879 | $85 |
| Long return visit (40+ min) | 30 | $4,818 | $118 |
| New patient visit (60+ min) | 16 | $2,742 | $171 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 33 | $2,736 | $83 |
| Critical care, each additional 30 minutes | 13 | $1,640 | $91 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 16 | $1,612 | $101 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $899 | $32 |
| Test to determine lung volumes using gas dilution or washout | 52 | $531 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 48 | $520 | $11 |
| Test to examine how well the lungs exchange gases | 52 | $394 | $8 |
2013: 12 services
| Critical care, first 30-74 minutes | 80 | $23,022 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 124 | $16,984 | $58 |
| Return visit (30+ min) | 72 | $12,013 | $87 |
| Long return visit (40+ min) | 34 | $4,503 | $119 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 31 | $2,677 | $31 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 27 | $2,294 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $1,983 | $83 |
| New patient visit (45+ min) | 11 | $1,493 | $136 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 12 | $1,243 | $89 |
| Test to determine lung volumes using gas dilution or washout | 31 | $335 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 30 | $323 | $11 |
| Test to examine how well the lungs exchange gases | 32 | $254 | $8 |
Medicaid work
$21,106 in 2024
Medicaid paid $21,106 for 246 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 246 | $21,106 |
| 2024 | 246 | 1 | 22 | $21,106 |
| 2023 | 377 | 1 | 24 | $34,508 |
| 2022 | 307 | 2 | 24 | $28,617 |
| 2021 | 155 | 1 | 15 | $13,292 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 377 | $34,508 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 289 | $27,123 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 18 | $1,494 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 155 | $13,292 |
Drugs they prescribed that Part D paid
$9,494
Pharmacies billed $9,494 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 58) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
27 generic and 31 brand-name prescriptions · $9,494 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Albuterol Sulfate Hfa | 23 | $301 | $13 |
Year by year
| 2024 | 58 | 28 | 0% (0) | 53% | $9,494 |
| 2023 | 215 | 57 | 0% (0) | 68% | $140,491 |
| 2022 | 490 | 99 | 0% (0) | 57% | $278,237 |
| 2021 | 329 | 57 | 0% (0) | 62% | $89,970 |
| 2020 | 494 | 77 | 0% (0) | 56% | $102,392 |
| 2019 | 616 | 107 | 0% (0) | 55% | $131,932 |
| 2018 | 629 | 122 | 0% (0) | 53% | $127,242 |
| 2017 | 812 | 140 | None | 49% | $128,334 |
| 2016 | 736 | 128 | None | 48% | $146,552 |
| 2015 | 796 | 133 | None | 47% | $128,623 |
| 2014 | 857 | 132 | 1% (11) | 53% | $132,991 |
| 2013 | 850 | 118 | None | 55% | $122,024 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Symbicort | 33 | $18,070 | $548 |
| Trelegy Ellipta | 12 | $15,628 | $1,302 |
| Flovent Hfa | 16 | $8,343 | $521 |
| Spiriva Respimat | 12 | $6,273 | $523 |
| Budesonide-Formoterol | 11 | $2,881 | $262 |
| Albuterol Sulfate Hfa | 43 | $1,638 | $38 |
| Montelukast | 19 | $268 | $14 |
2022: 11 drugs
| Ofev | 13 | $160,230 | $12,325 |
| Symbicort | 50 | $24,676 | $494 |
| Spiriva Respimat | 42 | $23,340 | $556 |
| Trelegy Ellipta | 12 | $12,677 | $1,056 |
| Flovent Hfa | 22 | $9,355 | $425 |
| Breo Ellipta | 16 | $8,234 | $515 |
| Fluticasone-Salmeterol | 28 | $5,479 | $196 |
| Wixela Inhub | 21 | $5,392 | $257 |
| Albuterol Sulfate Hfa | 96 | $3,982 | $41 |
| Montelukast | 51 | $1,052 | $21 |
| Fluticasone Propionate | 42 | $700 | $17 |
2021: 6 drugs
| Spiriva Respimat | 52 | $27,215 | $523 |
| Symbicort | 59 | $22,909 | $388 |
| Flovent Hfa | 13 | $10,456 | $804 |
| Albuterol Sulfate Hfa | 39 | $1,946 | $50 |
| Montelukast | 46 | $637 | $14 |
| Fluticasone Propionate | 18 | $268 | $15 |
2020: 12 drugs
| Symbicort | 67 | $25,855 | $386 |
| Spiriva Respimat | 32 | $15,808 | $494 |
| Flovent Hfa | 25 | $13,484 | $539 |
| Advair Diskus | 14 | $9,418 | $673 |
| Wixela Inhub | 24 | $7,229 | $301 |
| Albuterol Sulfate Hfa | 44 | $2,255 | $51 |
| Proair Hfa | 16 | $1,406 | $88 |
| Ventolin Hfa | 19 | $1,073 | $56 |
| Montelukast | 72 | $1,042 | $14 |
| Fluticasone Propionate | 41 | $695 | $17 |
| Ethambutol | 12 | $536 | $45 |
| Furosemide | 20 | $88 | $4 |
2019: 16 drugs
| Symbicort | 72 | $27,828 | $386 |
| Spiriva Respimat | 55 | $26,808 | $487 |
| Advair Diskus | 25 | $16,713 | $669 |
| Wixela Inhub | 19 | $7,697 | $405 |
| Flovent Hfa | 13 | $6,666 | $513 |
| Dulera | 13 | $5,052 | $389 |
| Proair Hfa | 38 | $2,605 | $69 |
| Fluticasone-Salmeterol | 15 | $2,588 | $173 |
| Montelukast | 72 | $1,321 | $18 |
| Ventolin Hfa | 20 | $1,220 | $61 |
| Fluticasone Propionate | 63 | $1,120 | $18 |
| Ethambutol | 11 | $701 | $64 |
| Hydroxyzine | 15 | $225 | $15 |
| Azithromycin | 19 | $179 | $9 |
| Prednisone | 17 | $169 | $10 |
| Furosemide | 23 | $84 | $4 |
2018: 12 drugs
| Symbicort | 85 | $31,918 | $376 |
| Advair Diskus | 54 | $29,611 | $548 |
| Spiriva Respimat | 56 | $27,359 | $489 |
| Proair Hfa | 42 | $3,188 | $76 |
| Montelukast | 94 | $1,635 | $17 |
| Ventolin Hfa | 21 | $1,621 | $77 |
| Fluticasone Propionate | 63 | $1,102 | $17 |
| Azithromycin | 16 | $435 | $27 |
| Methylprednisolone | 11 | $150 | $14 |
| Prednisone | 18 | $125 | $7 |
| Furosemide | 18 | $92 | $5 |
| Levofloxacin | 12 | $85 | $7 |
2017: 12 drugs
| Advair Diskus | 82 | $41,320 | $504 |
| Symbicort | 88 | $32,264 | $367 |
| Spiriva Respimat | 48 | $22,040 | $459 |
| Proair Hfa | 75 | $4,679 | $62 |
| Qvar | 12 | $2,550 | $212 |
| Ventolin Hfa | 33 | $1,876 | $57 |
| Montelukast | 136 | $1,874 | $14 |
| Fluticasone Propionate | 63 | $815 | $13 |
| Prednisone | 55 | $407 | $7 |
| Methylprednisolone | 26 | $290 | $11 |
| Azithromycin | 13 | $148 | $11 |
| Furosemide | 24 | $78 | $3 |
2016: 13 drugs
| Advair Diskus | 84 | $40,658 | $484 |
| Symbicort | 89 | $29,909 | $336 |
| Spiriva Respimat | 29 | $11,632 | $401 |
| Proair Hfa | 51 | $3,266 | $64 |
| Qvar | 12 | $2,428 | $202 |
| Montelukast | 109 | $1,596 | $15 |
| Ventolin Hfa | 17 | $1,088 | $64 |
| Sildenafil | 16 | $970 | $61 |
| Fluticasone Propionate | 44 | $511 | $12 |
| Methylprednisolone | 29 | $487 | $17 |
| Prednisone | 47 | $376 | $8 |
| Furosemide | 26 | $137 | $5 |
| Azithromycin | 16 | $135 | $8 |
2015: 16 drugs
| Advair Diskus | 100 | $41,271 | $413 |
| Symbicort | 66 | $20,222 | $306 |
| Spiriva | 37 | $18,994 | $513 |
| Proair Hfa | 71 | $4,785 | $67 |
| Spiriva Respimat | 13 | $4,501 | $346 |
| Dulera | 11 | $4,164 | $379 |
| Montelukast | 134 | $2,402 | $18 |
| Methylprednisolone | 24 | $515 | $21 |
| Prednisone | 52 | $493 | $9 |
| Fluticasone Propionate | 44 | $473 | $11 |
| Lansoprazole | 14 | $311 | $22 |
| Potassium Chloride | 15 | $212 | $14 |
| Losartan | 14 | $157 | $11 |
| Furosemide | 35 | $144 | $4 |
| Levofloxacin | 14 | $127 | $9 |
| Amlodipine Besylate | 19 | $77 | $4 |
2014: 16 drugs
| Advair Diskus | 112 | $46,717 | $417 |
| Spiriva | 71 | $30,109 | $424 |
| Symbicort | 67 | $21,003 | $313 |
| Proair Hfa | 84 | $5,258 | $63 |
| Montelukast | 119 | $3,844 | $32 |
| Nasonex | 14 | $2,926 | $209 |
| Ventolin Hfa | 19 | $1,046 | $55 |
| Lansoprazole | 19 | $956 | $50 |
| Fluticasone Propionate | 59 | $898 | $15 |
| Sildenafil | 11 | $762 | $69 |
| Hydrocodone-Acetaminophen | 11 | $560 | $51 |
| Prednisone | 53 | $472 | $9 |
| Methylprednisolone | 15 | $310 | $21 |
| Losartan | 20 | $249 | $12 |
| Levofloxacin | 16 | $194 | $12 |
| Furosemide | 33 | $187 | $6 |
2013: 19 drugs
| Advair Diskus | 94 | $35,319 | $376 |
| Spiriva | 51 | $20,524 | $402 |
| Symbicort | 73 | $19,819 | $271 |
| Dulera | 17 | $4,281 | $252 |
| Nasonex | 27 | $4,245 | $157 |
| Proair Hfa | 66 | $3,435 | $52 |
| Montelukast | 83 | $3,207 | $39 |
| Xopenex Hfa | 17 | $1,180 | $69 |
| Lansoprazole | 20 | $1,102 | $55 |
| Ventolin Hfa | 17 | $892 | $52 |
| Fluticasone Propionate | 33 | $839 | $25 |
| Hydroxyzine | 28 | $443 | $16 |
| Methylprednisolone | 14 | $330 | $24 |
| Furosemide | 48 | $312 | $7 |
| Prednisone | 43 | $281 | $7 |
| Atorvastatin | 11 | $258 | $23 |
| Klor-Con M20 | 11 | $179 | $16 |
| Ranitidine | 12 | $129 | $11 |
| Levofloxacin | 12 | $110 | $9 |
Money from drug and device companies
$116 in 2025
| 2025 | 1 | 1 | None | $116 |
| 2021 | 2 | 2 | None | $148 |
| 2019 | 1 | 1 | None | $149 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | None | $116 | 1 payment
|
See the published payment
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-09 | None | $116 |
See earlier years (2021, 2019)
2021: $148
| E.R. Squibb & Sons L.L.C. | Eliquis | $136 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Breztri | $12 | 1 payment
|
2019: $149
| Boston Scientific | General Pain Management | $149 | 1 payment
|
Professional record
- NPI
- 1154384105
- Licence
- CA A72347California A72347: Current · expires 2028-05-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A723470
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- Po Box 511225, Los Angeles, CA, 90051
- NPI first listed
- 2006-04-10
- NPI last updated
- 2010-06-22
This is when the NPI record was last certified, not a medical board exam.